Is Treatment With Convalescent Plasma Right for Your Patient

Your patient diagnosed with COVID-19 depends on you to prescribe the best treatment. One treatment option is transfusion of COVID-19 convalescent plasma (CCP). However, CCP is not uniformly efficacious for all patients. The CCP treatment benefit index (TBI) uses each patient’s clinical characteristics to guide your treatment decisions, predicting the relative benefit from CCP treatment as compared to treatment without CCP transfusion.

Take me to the Benefit Calculator

How Was The Covid-19 Convalescent Plasma Treatment Benefit Index Developed?

The COVID-19 convalescent plasma (CCP) treatment benefit index (TBI) was developed and tested using data from the Continuous Monitoring of Pooled International Trials of Convalescent Plasma (COMPILE) for COVID-19 Hospitalized Patients study. COMPILE included 8 international randomized controlled trials (RCTs) and has individual data on a total of 2369 hospitalized adults (18 years old or older) with COVID-19, who may or may not need oxygen supplementation, but do not require mechanical ventilation.

What Does the CCP TBI Measure?

The TBI has been further validated in 2 external RCTs and two external observational cohorts of patients treated with CCP. The treatment benefit is measured in terms of COVID-19 clinical status as assessed with the . The TBI score indicates the relative benefit the patient is expected to have from treatment with CCP compared to a treatment without CCP.

Our Team

The CCP-TBI was developed by the COMPILE statistics team, members of the Division of Biostatistics at the Department of Population Health, New York University Grossman School of Medicine.

Assistant Professor of Biostatistics
Professor of Biostatistics
Associate Research Scientist
Professor of Biostatistics
Professor of Cardiovascular Medicine
Professor of Biostatistics
Principal Investigator of COMPILE